Tenascin-C Is Increased in Inflammatory Bowel Disease and Is Associated with response to Infliximab Therapy

Abstract EN

Tenascin-C (TNC) is an extracellular matrix glycoprotein expressed in response to inflammation and tissue damage.

The role of TNC in patients with inflammatory bowel disease (IBD) is not well understood.

In this study, we analyzed the expression of TNC in the inflamed mucosa of patients with ulcerative colitis (UC) and Crohn’s disease (CD).

Serum TNC levels were determined by the enzyme-linked immunosorbent assay (ELISA), and the levels of TNC in patients with different disease activities were compared.

The expression of TNC was derived from a GEO dataset.

THP-1 cells were stimulated with TNC to evaluate the proinflammatory role of TNC.

We found higher TNC expression in the inflamed mucosa of patients with UC and CD compared with normal controls (NCs).

TNC was mainly expressed in the stromal area of the intestinal mucosa.

The median serum levels of TNC were significantly higher in UC (median 74.1 ng/ml, range 42.6–102.1 ng/ml) and CD (median 59.2 ng/ml, range 44.0–80.9 ng/ml).

We also found that serum TNC levels were correlated with Mayo scores in UC and Crohn’s disease activity index (CDAI) in CD.

Through GSE14580, we demonstrated that patients who were nonresponsive to infliximab treatment had higher mucosal TNC mRNA expression.

High TNC mRNA expression in the inflamed intestinal mucosa was associated with poor response to infliximab therapy in patients with UC.

Furthermore, THP-1 cells stimulated with TNC showed increased expression of IL-6, but not TNF-α, IL-8, MCP-1, or IL-1β.

Thus, increased TNC levels may participate in the pathogenesis of IBD and may serve as a biomarker for disease activity and response to treatment with infliximab.